Shanghai Pharmaceuticals Holding Co Ltd (SHPMY)
7.64
+0.16
(+2.14%)
USD |
OTCM |
May 22, 14:14
Shanghai Pharmaceuticals Enterprise Value: 8.695B for May 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 21, 2024 | 8.695B |
| May 20, 2024 | 9.110B |
| May 17, 2024 | 9.017B |
| May 16, 2024 | 9.017B |
| May 15, 2024 | 9.017B |
| May 14, 2024 | 9.206B |
| May 13, 2024 | 8.599B |
| May 10, 2024 | 8.599B |
| May 09, 2024 | 8.599B |
| May 08, 2024 | 8.636B |
| May 07, 2024 | 8.636B |
| May 06, 2024 | 8.340B |
| May 03, 2024 | 8.577B |
| May 02, 2024 | 8.469B |
| May 01, 2024 | 8.469B |
| April 30, 2024 | 8.717B |
| April 29, 2024 | 8.717B |
| April 26, 2024 | 8.799B |
| April 25, 2024 | 8.469B |
| April 24, 2024 | 8.599B |
| April 23, 2024 | 8.540B |
| April 22, 2024 | 8.428B |
| April 19, 2024 | 8.132B |
| April 18, 2024 | 8.231B |
| April 17, 2024 | 8.251B |
| Date | Value |
|---|---|
| April 16, 2024 | 8.339B |
| April 15, 2024 | 8.286B |
| April 12, 2024 | 8.317B |
| April 11, 2024 | 8.317B |
| April 10, 2024 | 8.310B |
| April 09, 2024 | 8.347B |
| April 08, 2024 | 8.206B |
| April 05, 2024 | 7.977B |
| April 04, 2024 | 8.566B |
| April 03, 2024 | 8.565B |
| April 02, 2024 | 8.677B |
| April 01, 2024 | 8.643B |
| March 31, 2024 | 8.551B |
| March 28, 2024 | 7.574B |
| March 27, 2024 | 7.821B |
| March 26, 2024 | 7.821B |
| March 25, 2024 | 7.874B |
| March 22, 2024 | 7.874B |
| March 21, 2024 | 7.647B |
| March 20, 2024 | 7.647B |
| March 19, 2024 | 7.711B |
| March 18, 2024 | 7.948B |
| March 15, 2024 | 7.948B |
| March 14, 2024 | 7.496B |
| March 13, 2024 | 8.030B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.167B
Minimum
Oct 07 2022
10.11B
Maximum
May 23 2023
8.092B
Average
8.109B
Median
Aug 25 2023
Enterprise Value Benchmarks
| Sinovac Biotech Ltd | -7.011B |
| CASI Pharmaceuticals Inc | 40.33M |
| Zai Lab Ltd | 1.373B |
| Gracell Biotechnologies Inc (DELISTED) | -- |
| Adagene Inc | 26.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 215.54M |
| Revenue (Quarterly) | 9.804B |
| Total Expenses (Quarterly) | 9.427B |
| EPS Diluted (Quarterly) | 0.2935 |
| Gross Profit Margin (Quarterly) | 11.44% |
| Profit Margin (Quarterly) | 2.20% |
| Earnings Yield | 9.45% |
| Operating Earnings Yield | 23.51% |
| Normalized Earnings Yield | 11.02 |